Correction: The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report

Caitlyn H Livingston,Benjamin Harper,Mathew George

DOI: https://doi.org/10.7759/cureus.c188

2024-08-09

Cureus

Abstract:[This corrects the article DOI: 10.7759/cureus.66240.].

What problem does this paper attempt to address?

Correction: Loss of EGFR Signaling-Regulated Mir-203 Promotes Prostate Cancer Bone Metastasis and Tyrosine Kinase Inhibitors Resistance

Man Kit Siu,Wassim Abou-Kheir,Juan,Yung-Chieh Chang,Ben Barrett,Florent Suau,Órla Casey,Wei-Yu Chen,Lei Fang,Paul G. Hynes,Yao-Yu Hsieh,Yen-Nien Liu,Jiaoti Huang,Kathleen Kelly

DOI: https://doi.org/10.18632/oncotarget.26020

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.1994.].
Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Frontiers Production Office

DOI: https://doi.org/10.3389/fphar.2022.1092147

IF: 5.6

2022-11-22

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.973448.].

pharmacology & pharmacy
Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Gang Chen,Peter Kronenberger,Erik Teugels,Ijeoma Adaku Umelo,Jacques De Grève

DOI: https://doi.org/10.1186/s12916-020-1501-8

IF: 9.3

2020-01-01

BMC Medicine

Abstract:Following publication of the original article [1], the authors reported that there was an error in Figure 9, which contained a misplaced picture. The authors confirm that all of the published results and conclusions of the paper remain unchanged, as well as the figure legends. The authors apologize for any confusion caused. The corrected Figure 9 is shown as follows:
Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Xinyang Liu,Shukui Qin,Zhichao Wang,Jianming Xu,Jianping Xiong,Yuxian Bai,Zhehai Wang,Yan Yang,Guoping Sun,Liwei Wang,Leizhen Zheng,Nong Xu,Ying Cheng,Weijian Guo,Hao Yu,Tianshu Liu,Pagona Lagiou,Jin Li

DOI: https://doi.org/10.1186/s13045-017-0545-5

IF: 28.5

2017-01-01

Journal of Hematology & Oncology

Abstract:The original article [1] contains two errors in Table 2
Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer

Abhishek Mahajan,Gurukrishna B,Shweta Wadhwa,Ujjwal Agarwal,Ujjwal Baid,Sanjay Talbar,Amit Kumar Janu,Vijay Patil,Vanita Noronha,Naveen Mummudi,Anil Tibdewal,J P Agarwal,Subhash Yadav,Rajiv Kumar Kaushal,Ameya Puranik,Nilendu Purandare,Kumar Prabhash

DOI: https://doi.org/10.37349/etat.2024.00248

Abstract:[This corrects the article DOI: 10.37349/etat.2023.00158.].
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Erratum: Nodular cutaneous metastasis of the leg in advanced urothelial bladder carcinoma: a case report and systematic literature review

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2023.1286604

IF: 4.7

2023-09-29

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1216725.].

oncology
Erratum: ITGA2 Overexpression Promotes Esophageal Squamous Cell Carcinoma Aggression via FAK/AKT Signaling Pathway [Corrigendum]

DOI: https://doi.org/10.2147/OTT.S390829

2022-09-27

Abstract:[This corrects the article DOI: 10.2147/OTT.S302028.].
Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

DOI: https://doi.org/10.1097/HS9.0000000000000987

2023-10-31

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000907.].
Erratum: Ophiopogonin-B Suppresses Epithelial-mesenchymal Transition in Human Lung Adenocarcinoma Cells via the Linc00668/miR-432-5p/EMT Axis: Erratum

Cheng Hu,Rilei Jiang,Ziyu Cheng,Yueyang Lu,Ling Gu,Hongxiao Li,Liqiu Li,Qian Gao,Meijuan Chen,Xu Zhang

DOI: https://doi.org/10.7150/jca.98604

2024-06-01

Abstract:[This corrects the article DOI: 10.7150/jca.31338.].
Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Gianluca Mauri,Giorgio Patelli,Viviana Gori,Calogero Lauricella,Benedetta Mussolin,Alessio Amatu,Katia Bencardino,Federica Tosi,Erica Bonazzina,Emanuela Bonoldi,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi

DOI: https://doi.org/10.3389/fonc.2023.1147497

IF: 4.7

2023-03-28

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1030232.].

oncology
The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution [Corrigendum]

Yitian Wang,Minxun Lu,Yong Zhou,Sisi Zhou,Xinzhu Yu,Fan Tang,Yi Luo,Wenli Zhang,Hong Duan,Li Min,Chongqi Tu

DOI: https://doi.org/10.2147/cmar.s279244

2020-09-01

Cancer Management and Research

Abstract:[This corrects the article DOI: 10.2147/CMAR.S254296.].

oncology
Erratum: Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy [Corrigendum]

DOI: https://doi.org/10.2147/JHC.S467902

2024-03-14

Abstract:[This corrects the article DOI: 10.2147/JHC.S444530.].
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong,Hui-Min Lei,Qian Liang,Ya-Bin Tang,Ye Zhou,Yang Wang,Shengzhe Zhang,Wen-Bin Li,Yunguang Tong,Guanglei Zhuang,Liang Zhang,Hong-Zhuan Chen,Liang Zhu,Ying Shen

DOI: https://doi.org/10.7150/thno.58558

IF: 11.6

2021-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.23177.].

medicine, research & experimental
Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Jomnarong Lertsuwan,Kornkamon Lertsuwan,Anyaporn Sawasdichai,Nathapol Tasnawijitwong,Ka Ying Lee,Philip Kitchen,Simon Afford,Kevin Gaston,Padma-Sheela Jayaraman,Jutamaad Satayavivad

DOI: https://doi.org/10.3390/cancers15010133

2022-12-26

Abstract:Authors would like to make a correction to the previous article [...].
Targeting The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Cells: The Effect Of Combining Rna Interference With Tyrosine Kinase Inhibitors Or Cetuximab (Vol 10, 28, 2012)

Gang Chen,Peter Kronenberger,Erik Teugels,Ijeoma Adaku Umelo,Jacques De Greve

DOI: https://doi.org/10.1186/s12916-020-1501-8

IF: 9.3

2020-01-01

BMC Medicine

Abstract:Following publication of the original article [1], the authors reported that there was an error in Figure 9, which contained a misplaced picture. The authors confirm that all of the published results and conclusions of the paper remain unchanged, as well as the figure legends. The authors apologize for any confusion caused. The corrected Figure 9 is shown as follows:
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne P. Robichaux,Yasir Y. Elamin,Zhi Tan,Brett W. Carter,Shuxing Zhang,Shengwu Liu,Shuai Li,Ting Chen,Alissa Poteete,Adriana Estrada-Bernal,Anh T. Le,Anna Truini,Monique B. Nilsson,Huiying Sun,Emily Roarty,Sarah B. Goldberg,Julie R. Brahmer,Mehmet Altan,Charles Lu,Vassiliki Papadimitrakopoulou,Katerina Politi,Robert C. Doebele,Kwok-Kin Wong,John V. Heymach

DOI: https://doi.org/10.1038/s41591-024-03178-1

IF: 82.9

2024-08-22

Nature Medicine

Abstract:Nature Medicine, Published online: 20 August 2024; doi:10.1038/s41591-024-03178-1 Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

biochemistry & molecular biology,cell biology,medicine, research & experimental
Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Hironaga Satake,Yu Sunakawa,Yuji Miyamoto,Masato Nakamura,Hiroshi Nakayama,Manabu Shiozawa,Akitaka Makiyama,Kazuma Kobayashi,Yutaro Kubota,Misuzu Mori,Masahito Kotaka,Akinori Takagane,Masahiro Gotoh,Masahiro Takeuchi,Masashi Fujii,Wataru Ichikawa,Takashi Sekikawa

DOI: https://doi.org/10.18632/oncotarget.25775

2018-07-06

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.24702.].
Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Chun-Ting Kuo,Chen-Lin Chen,Chih-Chi Li,Guan-Syuan Huang,Wei-Yuan Ma,Wei-Fan Hsu,Ching-Hung Lin,Yen-Shen Lu,Andrew M. Wo

DOI: https://doi.org/10.1038/s41598-020-68553-7

IF: 4.6

2020-08-19

Scientific Reports

Abstract:An amendment to this paper has been published and can be accessed via a link at the top of the paper.

multidisciplinary sciences
Erratum: "Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges". Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U. Wells and Manuela Funke-Chambour. ERJ Open Res 2022; 8: 00115-2022

DOI: https://doi.org/10.1183/23120541.50115-2022

2022-10-03

Abstract:[This corrects the article DOI: 10.1183/23120541.00115-2022.].

Correction: The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report

Correction: Loss of EGFR Signaling-Regulated Mir-203 Promotes Prostate Cancer Bone Metastasis and Tyrosine Kinase Inhibitors Resistance

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Erratum: Nodular cutaneous metastasis of the leg in advanced urothelial bladder carcinoma: a case report and systematic literature review

Erratum: ITGA2 Overexpression Promotes Esophageal Squamous Cell Carcinoma Aggression via FAK/AKT Signaling Pathway [Corrigendum]

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Erratum: Ophiopogonin-B Suppresses Epithelial-mesenchymal Transition in Human Lung Adenocarcinoma Cells via the Linc00668/miR-432-5p/EMT Axis: Erratum

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution [Corrigendum]

Erratum: Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy [Corrigendum]

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Targeting The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Cells: The Effect Of Combining Rna Interference With Tyrosine Kinase Inhibitors Or Cetuximab (Vol 10, 28, 2012)

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Erratum: "Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges". Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U. Wells and Manuela Funke-Chambour. ERJ Open Res 2022; 8: 00115-2022